We are live on ! Find out more
NGNE icon

Neurogene

33 hedge funds and large institutions have $183M invested in Neurogene in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

563% more capital invested

Capital invested by funds: $27.5M → $183M (+$155M)

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

22% more funds holding

Funds holding: 2733 (+6)

Holders
33
Holders Change
+6
Holders Change %
+22.22%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
10
Reduced
7
Closed
9
Calls
Puts
Net Calls
Net Calls Change

NGNE Hedge Fund Activity: Q3 2015 in Review

33 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2015, worth a combined $183M — up 563% from $27.5M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new NGNE positions and 9 closed out — a net gain of 6 holders — while 10 added to existing stakes and 7 trimmed.

The largest buyer was Baker Bros. Advisors, adding an estimated $63.9M. The largest seller was Broadfin Capital, exiting entirely with an estimated $3.69M sold.

  • 33 institutional investors held Neurogene (NGNE) as of Q3 2015, up from 27 in Q2 2015.
  • Funds reported $183M of Neurogene stock for Q3 2015, up 563% quarter-over-quarter.
  • 15 funds opened new Neurogene positions in Q3 2015 and 9 closed out, a net change of +6 holders.
  • The largest Neurogene buyer in Q3 2015 was Baker Bros. Advisors, an estimated $63.9M added.
  • The largest Neurogene seller in Q3 2015 was Broadfin Capital, an estimated $3.69M sold.

Based on aggregated 13F filings for Q3 2015.